Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking BioLife’s cryopreservation revenue or CGT logistics risks in a 300-page filing can drain hours. BioLife Solutions insider trading Form 4 transactions hide in dense tables, while critical 8-K updates on clinical-trial shipments surface without warning. If you have ever wondered, “How do I locate BioLife Solutions’ quarterly earnings report 10-Q filing in seconds?” Stock Titan delivers the answer.
Our platform ingests every submission the moment it hits EDGAR and feeds it to an AI engine that turns jargon into clarity. Need a BioLife Solutions annual report 10-K simplified? We highlight consumable sales growth, supply-chain quality metrics, and major risk factors. Looking for BioLife Solutions Form 4 insider transactions real-time? Instant alerts show which executives added shares. The AI also tags each BioLife Solutions proxy statement executive compensation section, unpacks option grants, and links them to performance goals. From BioLife Solutions earnings report filing analysis to a plain-English explainer of every BioLife Solutions 8-K material events explained, the information arrives ready to use.
Professionals rely on these insights to compare consumable-driven gross margins, monitor BioLife Solutions executive stock transactions Form 4 before therapy milestones, and evaluate liquidity through each BioLife Solutions SEC filings explained simply. Whether you are understanding BioLife Solutions SEC documents with AI for the first time or fine-tuning a DCF model, Stock Titan’s real-time coverage, AI-powered summaries, and historical archive of every filing form provide the edge you need—no more hunting through PDFs for the numbers that move CGT markets.
BioLife Solutions Inc. (BLFS)11/19/2025, 11/20/2025, and 11/21/2025. The reported transactions were sales of 477 shares at $24.50, 4,523 shares at $24.51, and 1,000 shares at $26.00, all coded as dispositions. After these trades, DuRoss beneficially owned 24,687 shares of BioLife Solutions common stock in direct ownership.
BioLife Solutions, Inc.
BioLife Solutions (BLFS) disclosed insider stock sales by its President and CEO, who is also a Director. The filing reports three open‑market sales of Common Stock: 35,417 shares at a weighted average price of $26.15 on 11/11/2025; 33,418 shares at $25.88 on 11/12/2025; and 31,165 shares at $25.33 on 11/13/2025.
Following these transactions, the executive’s directly held shares moved from 454,581 to 421,163 and then to 389,998. Each price is a weighted average, with individual trades executed within disclosed ranges.
BioLife Solutions (BLFS) reported Q3 results with total revenue of $28.1 million, up from $21.4 million a year ago, and net income of $0.6 million ($0.01 per share). Operating loss narrowed to $0.09 million, aided by $0.8 million in other income. For the first nine months, revenue was $77.4 million and net loss was $15.7 million, reflecting a $15.5 million IPR&D expense tied to the PanTHERA acquisition.
Cash, cash equivalents, and available-for-sale securities totaled $98.4 million at September 30, 2025. Year-to-date, operating cash flow was $15.2 million, investing used $72.7 million (including marketable securities purchases and IPR&D), and financing used $8.4 million as the company repaid $7.5 million on term loans. Shareholders’ equity was $353.7 million.
Management continues to focus on higher-margin bioproduction products after divesting several businesses in 2024. The company completed the PanTHERA transaction (accounted for as an asset acquisition) and, subsequent to quarter-end, signed an agreement to sell SAVSU, which remains in continuing operations for this period.
BioLife Solutions (BLFS) filed an 8-K announcing Q3 2025 results. The company reported that it issued a press release with unaudited financial results and operational highlights for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The filing classifies the update under Item 2.02 (Results of Operations and Financial Condition). BioLife’s common stock trades on the Nasdaq under the symbol BLFS.
BioLife Solutions (BLFS)Joydeep Goswami sold 1,666 shares of Common Stock on 10/24/2025 at a price of $28.99 per share, coded as an open-market sale (S). The transaction was executed under a Rule 10b5-1(c) trading plan effective 12/13/2024. Following this sale, Goswami beneficially owns 44,986 shares, held directly.
BioLife Solutions (BLFS) reported an insider transaction by its President & CEO and Director. On October 22, 2025, the reporting person sold 37,795 shares of common stock at $27.3 per share under a Rule 10b5-1(c) trading plan. Following the sale, the reporting person beneficially owns 489,998 shares, held directly.
The filing notes the 10b5-1 plan was effective October 19, 2023 and was adopted to satisfy tax withholding obligations related to the vesting of restricted stock.
BioLife Solutions (BLFS) filed a Form 4 indicating CTO Sean Werner sold 275 shares of common stock at $27.82 on October 20, 2025. The filing states the trade was executed under a Rule 10b5-1(c) plan adopted effective 07-17-2024 to satisfy tax withholding related to restricted stock vesting. Following the transaction, Werner beneficially owned 26,037 shares, held directly.
BioLife Solutions (BLFS) director Joydeep Goswami reported an open-market sale of 1,334 shares of common stock on 10/16/2025. The transaction was executed at a weighted average price with trade prices ranging from $28.99 to $29.00.
Following the sale, the reporting person beneficially owns 46,652 shares directly. The filing states the trades were made under a Rule 10b5-1(c) trading plan adopted effective 12/13/2024.
BioLife Solutions (BLFS): Casdin Partners Master Fund reported an open‑market sale of 750,000 shares of common stock on 10/15/2025 at a weighted average price of $28.5471, executed in multiple trades within the $28.50–$28.8354 range. After the transactions, 5,957,165 shares were beneficially owned indirectly. The shares are held directly by the Master Fund and may be deemed to be indirectly beneficially owned by Casdin Capital, Casdin Partners GP, and Eli Casdin.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
